Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

3 1 1 1

What is this study about?

This clinical trial is focused on studying a type of breast cancer known as Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. This type of cancer has spread beyond the breast and is not suitable for surgery aimed at curing it. The study will explore the effectiveness and safety of a new treatment combination. The treatment involves a medication called Giredestrant, which is taken as a capsule, combined with another medication called Everolimus, which is taken as a tablet. The study will compare this combination to the usual hormone therapy chosen by doctors, also combined with Everolimus.

The purpose of the study is to see how well the new treatment works in slowing down the progression of the cancer and to assess its safety. Participants will be randomly assigned to receive either the new treatment combination or the standard hormone therapy with Everolimus. The study will last for a period of up to 42 days, during which participants will take the medications orally. The study will also involve regular check-ups and monitoring to track the progress of the disease and any side effects that may occur.

By participating in this study, researchers aim to gather important information that could help improve treatment options for patients with this type of breast cancer. The study will focus on patients who have previously been treated with a type of medication called a CDK4/6 inhibitor and hormone therapy. The results will help determine if the new treatment combination is more effective than the current standard options available for managing this condition.

1 joining the study

Upon joining the study, eligibility is confirmed based on specific criteria, including the type of breast cancer and previous treatments.

A blood sample is required to determine specific genetic markers related to the cancer.

2 randomization

Participants are randomly assigned to one of two groups: one receiving giredestrant plus everolimus, and the other receiving a physician’s choice of endocrine therapy plus everolimus.

3 treatment administration

For those receiving giredestrant, it is administered orally in capsule form.

The dosage and frequency of everolimus depend on the specific product used, with options including 2.5 mg, 5 mg, and 10 mg tablets taken orally.

Participants in the physician’s choice group may receive medications such as tamoxifen (20 mg tablets), fulvestrant (250 mg injection), or exemestane (25 mg tablets), depending on the physician’s decision.

4 monitoring and assessments

Regular assessments are conducted to monitor the progression of the disease and the body’s response to the treatment.

These assessments include imaging tests and evaluations of symptoms and side effects.

5 follow-up

Participants continue to be monitored for progression-free survival, which is the time during and after treatment that the patient lives with the disease without it getting worse.

Additional follow-up includes monitoring overall survival and quality of life measures.

Who Can Join the Study?

The patient must have locally advanced or metastatic breast cancer that cannot be treated with the aim of curing it. This means the cancer has spread beyond the breast and nearby areas and cannot be completely removed or cured.
The cancer must be estrogen receptor-positive (ER+), which means the cancer cells grow in response to the hormone estrogen. This is determined by a test showing that at least 1% of the cancer cells have this characteristic.
The cancer must be HER2-negative, meaning it does not have high levels of a protein called HER2, which can promote the growth of cancer cells.
The patient must be able to provide a blood sample to check for a specific change in the cancer’s DNA, known as the ESR1 mutation.
The patient must have measurable disease, which means the cancer can be measured by scans or tests. If the cancer has spread to the bones, there must be at least one area in the bones that can be seen and measured on a CT or MRI scan.
Any side effects from previous cancer treatments or surgeries must have improved to a mild level, as defined by a specific medical guideline.
The study is open to both female and male patients.

Who Cannot Join the Study?

Patients who have not been previously treated with a CDK4/6 inhibitor and endocrine therapy. A CDK4/6 inhibitor is a type of medication used to treat certain breast cancers, and endocrine therapy is a treatment that blocks or lowers the amount of hormones in the body to slow down or stop cancer growth.
Patients with breast cancer that is not Estrogen Receptor (ER)-Positive or HER2-Negative. ER-Positive means the cancer cells grow in response to the hormone estrogen. HER2-Negative means the cancer does not have high levels of the protein HER2.
Patients who do not have locally advanced or metastatic breast cancer. Locally advanced means the cancer has spread to nearby tissues or lymph nodes, and metastatic means the cancer has spread to other parts of the body.
Patients who are not part of the ESR1m subpopulation. This refers to a specific group of patients with a mutation in the estrogen receptor 1 gene.
Patients who are not part of the intent-to-treat (ITT) population. This means all patients who are intended to be treated in the study, regardless of whether they complete the treatment.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz	Mainz	Germany

Other Sites

Site Name	City	Country
Azienda Ospedaliero Universitaria Di Modena	Modena	Italy
Hospital General Universitario Gregorio Maranon	Madrid	Spain
Hospital Universitari Dexeus Grupo Quironsalud	Barcelona	Spain
Metropolitan General Hospital/Healthcare Facilities Operation And Management Single Member S.A	Cholargos	Greece
Saarland University Hospital	Homburg	Germany
Foueshkxcl Hernsazg Hsokobliez	Georgsmarienhütte	Germany
Gvcfzri Uthkheoimk Hiyzxvhx Og Lxvrssf	Larissa	Greece
Hmlyeoiu Umuaplrerxujd dg A Ccdypt	A Coruna Galicia	Spain
Ufcyclmeihfvlwgfrtzgw Eogxrtry Any	Erlangen	Germany
Acpi Ghrpdz Ooyqjccj Msfhlpzorgwls Nekuhmut	Milan	Italy
Uvesevlueleywvtzz Dnedm Sphgh Dt Vkvgqu	Verona	Italy
Aghdsdnqv Hmbznvaa	Athens	Greece
Hdakerfv Cyqwhr Db Blkdzereo	Barcelona	Spain
Uxhrwzwqwascyovfetfhi Dvjlfefbdpo Aax	Duesseldorf	Germany
Ibszr Ocnciwvq Pefqhxviuef Siq Mvxqqqx	Genoa	Italy
Uztspfayiyyrfybyd Pnefyxcxzun Deghj Mgqdlh	Ancona	Italy
Hqjdqvsp Ctcyyju Shr Codxws	Madrid	Spain
Upmpipjnqyejqzjooodjy Mswwruqd Auo	Munster	Germany
Gaoslif Ufjqitsxci Hbilqryb Os Ppnctz	Patras	Greece
Urkkxjrbodwpkskboookl Hqatieqssd Axm	Heidelberg	Germany
Afrtbn Mxamtxv Cmoykx Sebz	Thessaloniki	Greece
Idtlqh Irvtsnhu Fjtjqtgfdctug Okztpohpyza	Rome	Italy
Mffrsokjgofojt Bwyufgs gwvea	Bottrop	Germany
Hbveedqe Uelkxacdoiozi 1l Ds Oavixan	Madrid	Spain
Ugyzrkmskxuaxfaiw Dpybx Suffn Dc Fkkzzyn	Ferrara	Italy
Uamgealmci Grterjb Hejepzbi Ox Hlhiuoezj	Heraklion	Greece
Hgtrucwt Ufkkqxtppvuyt Vladie Dp Lel Nwydgt	Granada	Spain
Fivtjduszq Ixvoy Suo Gzssgco Dum Tbbqawg	Monza	Italy
Upjdenxvec Guzkalc Hljriynv Aepudyj Gpcizps Hknwbuxl Oi Wdms Ammktl H Aflw Vjbxxro	Chaidari	Greece
Memiza Cdcxql Ceetxe Hhmsifkp Oi Pfhmfqt	Piraeus	Greece
Djv Amdl Mihygskadnou Vuhiyuakee Gzxq	Erfurt	Germany
Igpd Gmgyz	Filothei	Greece
Spe Ljjilpmjrpvf Hykgtdrc Syly	Thessaloniki	Greece
Koqhs Sui Ptzocm Gjgr	Dortmund	Germany
Hiuqnahp Gvzhsdn Uhtofzqbdkbln Mdwzlrx Mvaarstn	Murcia	Spain
Eiguwtficm Gkaqtuj Cbrtve Oy Thfnoabskmxq	Thessaloniki	Greece
Ozwmyzck Tsobicgdkmkqf Gmqqvsm Cpahyc Oo Pmhodh Sywm	Patras	Greece

Trial status

Country	Status	Recruitment Start
Germany	Not recruiting	30.10.2023
Greece	Not recruiting	30.10.2023
Italy	Not recruiting	30.10.2023
Spain	Not recruiting	30.10.2023

Trial locations

Investigated Drugs:

Giredestrant is a medication being studied for its potential to treat breast cancer. It works by targeting and blocking the estrogen receptor, which can help slow down or stop the growth of cancer cells that rely on estrogen to grow.

Everolimus is a medication used in this trial to help treat breast cancer. It works by interfering with the cancer cells’ ability to grow and divide. It is often used in combination with other treatments to enhance its effectiveness.

Endocrine Therapy refers to a group of treatments that aim to block or lower the amount of hormones in the body, particularly estrogen, to slow down or stop the growth of hormone-sensitive tumors. In this trial, the specific type of endocrine therapy is chosen by the physician based on the patient’s needs.

Investigated Diseases:

Estrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer – This type of breast cancer is characterized by the presence of estrogen receptors on the surface of the cancer cells, which means the cancer cells may receive signals from estrogen that could promote their growth. It is HER2-negative, indicating that the cancer cells do not have an excess of the HER2 protein on their surfaces. The disease can be locally advanced, meaning it has spread beyond the breast to nearby tissues, or metastatic, indicating it has spread to other parts of the body. Patients with this type of cancer have typically been previously treated with a CDK4/6 inhibitor and endocrine therapy. The progression of the disease involves the growth and spread of cancer cells, which can lead to various symptoms depending on the areas affected. The focus of ongoing studies is to evaluate the effectiveness of different treatment combinations in managing the progression of this cancer.

Trial ID:

2023-506821-12-00

Protocol code:

ML43171

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?